β-blockade in hypertension and congestive heart failure

Journal of Cardiovascular Pharmacology

Volumn 38, Issue SUPPL. 3, 2002, Pages

  Ambrosioni, E ^a   Bacchelli, S ^a   Esposti, D D ^a   Borghi, C ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Heart failure; Hypertension; blockers

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; PROPRANOLOL; THIAZIDE DIURETIC AGENT;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; STROKE; SURVIVAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0036136151     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200112003-00005     Document Type: Article

References (74)

1. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Over-view of randomised drug trials in their epidemiological context
2. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program
3. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
4. Medical Research Council trial of treatment of hypertension in older adults: Principal results
5. Public health issues in hypertension control: What has been learned from clinical trials
6. Treatment of hypertension in the elderly
7. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg
8. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg
9. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial
10. Shanghai trial of nifedipine in the elderly (STONE)
11. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
12. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure
13. MRC trial of treatment of mild hypertension: Principal results
14. Cardiovascular risk and risk factors in a randomized trial of treatment based on the β-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH)
15. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPY trial
16. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis
17. Diuretics, beta-blockers, and gin and tonic
18. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?
19. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study
20. Primary prevention of sudden cardiovascular death in hypertensive patients: Mortality results from the MAPHY study
21. British MRC trial of treatment for mild hypertension: A more favorable interpretation
22. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study
23. Beta blockade during and after myocardial infarction: An overview of the randomized trials
24. Beta-blockers for hypertension: Time to call a halt
25. Beta-blockers in hypertension: To reappraise or to call a halt?
26. The place for beta-blockers in treating hypertension
27. Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension
28. Beta-blockers: A time for reappraisal
29. The place of beta-blockers in cardiovascular medicine
30. Randomised trial of treatment of hypertension in elderly patients in primary care
31. Reducing the risk for coronary heart disease and stroke in hypertensives-comments on mechanisms for coronary protection and quality of life
32. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries
33. Nebivolol vs atenolol and placebo in essential hypertension: A double-blind randomised trial
34. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension
35. Endothelial function and antihypertensive treatment
36. Treatment of congestive heart failure. Has the time come for decreased complexity?
37. The effect of beta-adrenergic blockade on patterns of urinary sodium excretion: Studies in normal subjects and in patients with heart disease
38. Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure
39. Beta-blockade in heart failure. Basic concepts and clinical results
40. Beta-blocking agents in heart failure. Should they be used and how?
41. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: An analysis of studies published in the literature
42. Effects of beta-adrenergic blocking therapy on left ventricular diastolic relaxation properties in patients with dilated cardiomyopathy
43. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction
44. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage
45. Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure
46. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy
47. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade
48. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy
49. A randomized trial of beta-blockade in heart failure
50. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
51. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure
52. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
53. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction
54. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
55. Clinical effects of beta-adrenergic blockade in chronic heart failure
56. Effects of beta-blocker therapy on mortality in patients with heart failure: A systematic overview of randomized controlled trials
57. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
58. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial
59. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF): Mortality results
60. The evidence for beta-blockers in heart failure
61. Beta-blockers for advanced heart failure - How far can you go?
62. Beta-blockers for mild to moderate heart failure
63. Beta-blocker therapy in advanced heart failure: Clinical characteristics and long-term outcomes
64. The role of third-generation beta-blocking agents in chronic heart failure
65. Haemodynamic effect of nebivolol in patients with coronary artery disease
66. Pilot study of cardiovascular effects of nebivolol in congestive heart failure
67. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy
68. Nebivolol in the treatment of cardiac failure: A double-blind controlled clinical trial
69. Administration of nevibolol after coronary artery bypass in patients with altered left ventricular function
70. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: Comparison with D-L-nebivolol and atenolol
71. Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure
72. Medium-term effects of beta-blockade on left ventricular mechanics: A double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction
73. Enhanced nitric oxide production in heart failure: Another failed counter-regulatory mechanism?
74. Increased nitric oxide production in heart failure